In a clinical context, blood-based mRNA biomarkers, including glial fibrillary acidic protein (GFAP) and neurogranin (NRGN), have shown potential in predicting stroke severity and functional outcomes (Bustamante et al., 2017). This evidence concerns the gene NRGN and Stroke.